A Study on TLC590 for Managing Postsurgical Pain

Purpose

This Phase 2 open-label trial investigates the pharmacokinetics (PK), pharmacodynamics, and safety profile of TLC590 across various surgical procedures. Researchers aim to determine the maximum tolerated dose (MTD) of TLC590 via Safety Monitoring Committee (SMC). The study evaluates TLC590 in bunionectomy, laparoscopy-assisted open ventral hernia repair, breast augmentation, abdominoplasty, and total knee arthroplasty models. Additionally, it determines the relative bioavailability of TLC590 to ropivacaine injection.

Condition

  • Postsurgical Pain Management

Eligibility

Eligible Ages
Between 18 Years and 70 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Able and willing to provide written informed consent 2. Male or female aged 18 to 70 years, inclusive. For the Part 2 breast augmentation surgical model, only females can be enrolled 3. Scheduled to undergo one of the following elective surgeries, with no additional procedures and be able to use the anesthesia regimen: 1. Unilateral first metatarsal bunionectomy (Cohort 1) 2. Laparoscopy-assisted open ventral hernia repair (Cohort 2 and 6) 3. Breast augmentation (Cohort 3 through 5) 4. Unilateral total knee arthroplasty (Cohort 7) 5. Abdominoplasty (tummy tuck) (Cohort 8) 4. ASA Physical Status Classification of 1 or 2 5. Male subjects must be either biologically or surgically sterile or commit to the use of a reliable method of birth control (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence for the duration of the study and for 30 days after study drug administration 6. Female subjects are eligible only if all the following apply: 1. Not pregnant with a negative serum pregnancy test at Screening and negative urine pregnancy test on Day 1 before surgery (pregnancy test not required for females of non-childbearing potential, defined as surgically sterile or post-menopausal) 2. Not lactating 3. Not planning to become pregnant during the study 4. If of childbearing potential, commits to the use of a highly effective method of birth control for the duration of the study and or at least 30 days after study drug administration 7. BMI >18 ~ ≤39 kg/m2

Exclusion Criteria

  1. A clinically significant abnormal clinical laboratory test value 2. Evidence of a clinically significant 12-lead ECG 3. History of orthostatic hypotension, syncope, or other syncopal attacks 4. History or any clinical manifestation of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other condition that has been assessed by the Investigator to be unsuitable for participation in the study 5. History of seizures or taking anticonvulsants during the Screening period 6. History of cardiac arrhythmia or taking Class III antiarrhythmic drugs including amiodarone, dofetilide, dronedarone, sotalol, or ibutilide during the Screening period 7. History of sleep apnea or on home CPAP treatment 8. History of hypersensitivity to ropivacaine, any other amide-type local anesthetic, propofol, hydromorphone, fentanyl, midazolam, acetaminophen, oxycodone, or morphine (or other opioids) 9. History of severe or refractory PONV due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer, deemed clinically significant by the Investigator 10. Any lifetime history of a suicidal attempt or any suicidal behavior, as assessed by the C-SSRS at Screening 11. History or positive test results of HIV, HCV, or HBV 12. History or current report of substance abuse including illicit drug abuse and/or alcohol abuse (regularly drinks >4 units of alcohol per day: 1 unit = 8 oz. beer, 3 oz. wine, or 1 oz. spirits) within 2 years prior to Screening 13. Positive results on the urine drug screen or alcohol breath test indicative of illicit drug or non-prescribed drug or alcohol abuse at Screening or on Day 1 before surgery. Prescribed medication that is known to result in a positive drug test is allowed. Marijuana (medical or recreational) is not allowed 14. Pre-existing concurrent acute, or chronic painful restrictive/physical condition that may confound postoperative pain assessments or is expected to require analgesic treatment during the study 15. Has known or suspected daily use of opioids for longer than 4 days per week within the previous 6 months prior to Screening 16. Is taking daily analgesics for longer than 4 days per week for a chronically painful condition during the Screening period. Not exclusionary if it is utilized for pain related to the total knee arthroplasty indication 17. Is receiving oxygen therapy during the Screening period 18. Use of any of the following medications within 5 half-lives prior to the study surgical procedure or as specified 19. Malignancy in the last 2 years prior to Screening, except for non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix 20. Personal or family history of malignant hyperthermia

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Part 1, Cohort 1 		Bunionectomy: Increasing dose cohorts for TLC590
  • Drug: TLC590
    Sequentially enrolled into increasing dose cohorts from low to high to receive a dose of TLC590
    Other names:
    • TLC590 (Ropivacaine Extended-Release Injectable Suspension)
Experimental
Part 1, Cohort 2 		Laparoscopy-assisted Open Ventral Hernia: TLC590
  • Drug: TLC590
    TLC590
    Other names:
    • TLC590 (Ropivacaine Extended-Release Injectable Suspension)
Experimental
Part 2, Cohort 3 		Breast Augmentation: TLC590 or Ropivacaine
  • Drug: TLC590
    TLC590 Dose 1
    Other names:
    • TLC590 (Ropivacaine Extended-Release Injectable Suspension)
  • Drug: Ropivacaine
    Ropivacaine
    Other names:
    • Ropivacaine HCL Injection
Experimental
Part 2, Cohort 4 		Breast Augmentation: TLC590 or Ropivacaine
  • Drug: TLC590
    TLC590 Dose 2
    Other names:
    • TLC590 (Ropivacaine Extended-Release Injectable Suspension)
  • Drug: Ropivacaine
    Ropivacaine
    Other names:
    • Ropivacaine HCL Injection
Experimental
Part 2, Cohort 5 		Breast Augmentation: TLC590 with the SMC-suggested dose
  • Drug: TLC590
    TLC590 Dose 3 (The SMC-suggested dose)
    Other names:
    • TLC590 (Ropivacaine Extended-Release Injectable Suspension)
Experimental
Part 3, Cohort 6 		Laparoscopy-assisted Open Ventral Hernia: The MTD of TLC590
  • Drug: TLC590
    The MTD of TLC590
    Other names:
    • TLC590 (Ropivacaine Extended-Release Injectable Suspension)
Experimental
Part 3, Cohort 7 		Total Knee Arthroplasty: The MTD of TLC590
  • Drug: TLC590
    The MTD of TLC590
    Other names:
    • TLC590 (Ropivacaine Extended-Release Injectable Suspension)
Experimental
Part 3, Cohort 8 		Abdominoplasty: The MTD of TLC590
  • Drug: TLC590
    The MTD of TLC590
    Other names:
    • TLC590 (Ropivacaine Extended-Release Injectable Suspension)

Recruiting Locations

Memorial Hermann Village
Houston, Texas 77043
Contact:
Dominick S. D'Aunno, MD

More Details

Status
Recruiting
Sponsor
Taiwan Liposome Company

Study Contact

Grace Tsao
+886-2-26557377
grace@tlcbio.com

Detailed Description

This Phase 2, open-label, multi-center study is a 3-part study to be performed in approximately 120 subjects undergoing multiple surgical procedures receiving TLC590 or ropivacaine injection. Subjects eligible based on inclusion and exclusion criteria will receive study drug administered via infiltration. Subjects entering all parts of the study will undergo the consent and screening procedures, eligibility requirements, and PK and safety evaluations during their participation in the study.